ImmuCell
Portland, Maine, United States · Agriculture and Farming, Animal Feed, Biotechnology
ImmuCell Corporation is a growing animal health company that develops, manufactures, and markets scientifically proven and practical products aimed at improving the health and productivity of dairy and beef cattle. The company is known for its product First Defense®, which provides immediate immunity to newborn calves, and is developing Re-Tain®, a treatment for subclinical mastitis in dairy cows.
Key facts
- Headquarters
- Portland, Maine, United States
- Employees
- 45
- Industries
- Agriculture and Farming, Animal Feed, Biotechnology
- Status
- Public (ICCC)
- Website
- immucell.com
- Company page
Recent activity at ImmuCell
ImmuCell funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2016 | Seed | $3.5M |
Leadership
- LINDA RHODES, Director
- DAVID TOMSCHE, Director
- PAUL WAINMAN, Director
- JONATHAN ROTHSCHILD, Director
- DAVID CUNNINGHAM, Director
- JOSEPH CRABB, Executive Officer, Director
- MICHAEL BRIGHAM, Executive Officer, Director
- Olivier te Boekhorst, Chief Executive Officer
- Timothy C. Fiori, Chief Financial Officer
- ELIZABETH WILLIAMS, Executive Officer
- BOBBI BROCKMANN, Executive Officer
Verified email and direct lines for ImmuCell’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
ImmuCell files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
ImmuCell in the news
- The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell - Yahoo Finance (Sep 29, 2026)
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026 - Moomoo (Aug 06, 2026)
- ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand - Yahoo Finance (May 25, 2026)
- ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results - The Manila Times (Oct 12, 2026)
- Portland biotech firm ImmuCell completes $20 million expansion - Portland Press Herald - Maine Sunday Telegram (Nov 07, 2017)
- The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell - Yahoo Finance (Jun 26, 2026)
- ImmuCell (Nasdaq:ICCC) - Stock Analysis - Simply Wall St (Dec 01, 2017)
Companies similar to ImmuCell
- Elanco Animal Health · Agriculture and Farming, Animal Feed, Biotechnology, Health Care, Manufacturing
- Shape Memory Medical · Biotechnology, Healthcare, Health Care, Manufacturing
- NOWDiagnostics, Inc. · Biotechnology, Healthcare, Health Care, Manufacturing
- Omniscient Neurotechnology · Biotechnology, Healthcare, Health Care, Manufacturing
- CurvaFix · Biotechnology, Healthcare, Health Care, Manufacturing
About ImmuCell: questions and answers
What does ImmuCell do?
ImmuCell Corporation is a growing animal health company that develops, manufactures, and markets scientifically proven and practical products aimed at improving the health and productivity of dairy and beef cattle. The company is known for its product First Defense®, which provides immediate immunity to newborn calves, and is developing Re-Tain®, a treatment for subclinical mastitis in dairy cows.
Where is ImmuCell headquartered?
ImmuCell is headquartered in Portland, Maine, United States.
How many employees does ImmuCell have?
ImmuCell has about 45 employees.
Has ImmuCell raised funding?
Yes. Fundz has recorded 1 funding event for ImmuCell. The most recent, Seed of $3.5M, was in Oct 2016.
Who leads ImmuCell?
Olivier te Boekhorst is a Chief Executive Officer at ImmuCell.
What is the latest news on ImmuCell?
On Nov 04, 2025, ImmuCell Corporation Appoints Olivier te Boekhorst as President and CEO
Is ImmuCell a public company?
Yes. ImmuCell is publicly traded under the ticker ICCC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy